Brief: Cyclerion Announces IW-6463 Phase 1 Healthy Volunteer Study Results That Support Further Development For Neurodegenerative Diseases

Korsana Biosciences

13/01/2020 14:24

Jan 13 (Reuters) - Cyclerion Therapeutics Inc  CYCN.O :
    * CYCLERION ANNOUNCES IW-6463 PHASE 1 HEALTHY VOLUNTEER
STUDY
RESULTS THAT SUPPORT FURTHER DEVELOPMENT FOR NEURODEGENERATIVE
DISEASES
    * CYCLERION THERAPEUTICS SAYS STUDY RESULTS DEMONSTRATED
THAT
IW-6463 WAS WELL TOLERATED ACROSS TESTED DOSE LEVELS - SEC
FILING

Source: (http://bit.ly/37UbrRg)
Further company coverage:  CYCN.O 

 ((Reuters.Briefs@thomsonreuters.com;))